
Opinion|Videos|October 29, 2025
Translating Real-World Outcomes in mCRC Into Patient Conversations
Panelists discuss how real-world outcomes inform patient conversations and support shared decision-making for third-line metastatic colorectal cancer therapies.
Advertisement
Episodes in this series

Panelists highlight how real-world outcomes shape patient discussions, especially when setting realistic expectations about efficacy, safety, and quality of life with third-line options.
They note that real-world evidence with trifluridine/tipiracil plus bevacizumab and with fruquintinib confirms trial findings, providing confidence to patients about likely benefits.
By framing treatment conversations around both clinical data and real-world outcomes, clinicians can foster shared decision-making that aligns patient goals with available therapies.
Advertisement
Related to this article

CRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic differences remain unclear.

San Francisco experts say earlier IgA nephropathy and FSGS detection depends on primary care education and care coordinators.

The FDA has approved secukinumab for PMR after the REPLENISH trial showed doubled sustained remission and lower steroid use vs a steroid taper alone.

Earlier MASH fibrosis detection is more urgent now that treatments exist, and automating FIB-4 in EHRs could help primary care, says Rohit Loomba, MD.

In this Q&A, Jesús Corral Jaime, MD, discusses real-world CEMI-LUNG data on cemiplimab in advanced NSCLC presented at the ESMO 2026 Congress.

Neladalkib earned accelerated approval for previously treated ALK-positive NSCLC, with ORRs of 49% and 32%.

FDA approved adrabetadex for infantile-onset Niemann-Pick disease type C after survival data showed 84% vs 42% 5-year survival with treatment.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First siRNA Therapy for AChR-Positive Myasthenia Gravis
2
Complicated UTI Care Strained by Unclear Goals, Access Gaps
3
Obesity Care Ownership Shifts to Specialties That Win Coverage
4
Iron Deficiency in Heart Failure Is a Workflow Problem, Faculty Say
5

